with specific focus on those switching to a simplified regimen of premixed insulin. Characteristics were described at treatment initiation or on 1 January 2005, and treatment patterns were assessed at 12 months of follow-up. Clinical factors were compared in two groups of patients who while receiving BB had one haemoglobin A1c (HbA1c) measurement of C53 mmol/mol (7.0%) and remained either on BB or switched to a premixed insulin regimen.
Results: Study criteria were met by 12,060 subjects (mean age 59 years; duration diabetes 12.4 years). The mean HbA1c concentration was 76 mmol/mol (9.1% of patients), and 84.0% of patients were overweight. At 12 months of follow-up, 74.5% of the patients who had started BB remained on it. While on BB, 8835 patients had a HbA1c measurement of C53 mmol/mol (7.0% of all patients); of these, 95.9% remained on BB and 4.1% switched to premixed insulin. Mean HbA1c levels were consistently higher for patients who switched to premixed insulin than for those who remained on BB, but the levels remained relatively unchanged over time.
Conclusion: A large proportion of patients receiving insulin did not achieve good glycaemic control in clinical practice. A small
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INTRODUCTION
The prevalence of diagnosed diabetes in the UK rose from 1.4 million in 1996 to almost 3.5 million in 2014. More than one in 16 people have diabetes, of whom 90% have type 2 diabetes mellitus (T2DM) [1, 2] . Increasing emphasis is being placed on the appropriate use of insulin among patients with T2DM, with the aim to control the blood glucose so that the haemoglobin A1c (HbA1c) level remains below the general target of 53 mmol/mol (7.0%) for adults on a drug associated with hypoglycaemia, with the optimal HbA1c targets determined by both patient and disease characteristics, as specified by diabetes management guidelines [3, 4] . Clarity on how to use insulin is important given evidence from studies in the UK showing that the timing of the initiation and intensification of insulin therapy is often suboptimal [5] .
The UK National Institute for Health and Care Excellence (NICE) guidelines on T2DM [3] recommend initiating insulin therapy as the second intensification step. Depending on lifestyle and risk of hypoglycaemia, a number of choices are available to the patient. If the patient's HbA1c level is C75 mmol/mol (9.0%), then consideration should be given to starting both neutral protamine Hagedorn insulin and short-acting insulin administered either separately or as a premixed human insulin preparation. The guidelines suggest that adults using basal insulin be monitored to determine the need for treatment intensification with an additional short-acting (or premixed) insulin injection before meals (bolus insulin). Recent data provide evidence that therapy with both basal and prandial insulin results in better glycaemic control than basal insulin treatment alone [6, 7] . Few studies have examined the extent to which the NICE guidelines for insulin intensification are followed in primary care settings in the UK. Gallagher et al. [8] investigated the effect of financial incentives introduced in the UK in 2004 and found that proportionately more patients with T2DM
received pharmacological treatment after the incentives were enacted; however, this study, did not examine clinical outcomes. A recent study by Khunti et al. [9] showed that amongst patients with an HbA1c level of C58 mmol/mol (7.5%), 30.9% had their regimen intensified, taking place on average 3.7 years after the initiation of insulin therapy. Barriers to initiation and intensification, such as the high injection frequency required with a basal-bolus (BB) insulin regimen and subsequent non-compliance with the treatment, [10, 11] , have been identified [12] . A recent position statement of the American Diabetes Association insulin ? a rapid-acting (mealtime) insulin injection or premixed insulin therapy [4] .
Premixed insulin, which requires fewer daily injections, may be an alternative [13] . A meta-analysis by Wang et al. [14] 
METHODS
This study used longitudinal data from the Clinical Practice Research Datalink (CPRD) database, which integrates primary care records with prescription data and represents approximately 7.0% of the UK population. This is an appropriate source of data for this study as general practitioners (GPs) are the main healthcare providers for patients with T2DM in the UK [15, 16] . The CPRD is a fully anonymised database using a random number as the patient identifier, and details on the CPRD have been previously published [17, 18] .
The study objectives were addressed by analysing two specific, but related, samples that were drawn from patients diagnosed with 
Comparison Sample
The sample of patients with T2DM who started a BB insulin regimen and had at least one HbA1c measurement of C53 mmol/mol (C7.0%) while receiving BB insulin was used to compare the characteristics and outcomes of those who remained on their BB regimen with those who switched to premixed insulin during the 12 months after their HbA1c
C53 mmol/mol (C7.0%) measurement. The index date for this sample was the first HbA1c measurement of C53 mmol/mol (C7.0%) after the initiation of BB insulin therapy.
Study Measures
Age, sex, smoking status and comorbidities previously analysed by Blak et al. [19] (cancer, cerebrovascular disease, congestive heart failure, coronary artery disease, depression, diabetic nephropathy, diabetic neuropathy, Analyses were conducted using SAS software (ver. 9.4; SAS Institute, Cary, NC). 
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RESULTS
Study Samples
Overall, 210,778 people were identified in the CPRD database with T2DM diagnosed prior to 1 January 2013; of these, 12,060 people met our inclusion/exclusion criteria and received BB (Fig. 1) . The sample for the comparative analyses included 8835 individuals with T2DM who did not achieve the glycaemic control target of a HbA1c level of\53 mmol/mol (7.0%) under their BB insulin regimen and who either remained on BB therapy (8471 patients, 95.9%) or who switched to a premixed insulin therapy (364 patients, 4.1%). Although average HbA1c levels and the prevalence of a HbA1c level of [64 mmol/mol (8.0%) were consistently higher for patients who switched to premixed insulin than for those remaining on their BB insulin regimens (p\0.01 for all time intervals), they remained relatively unchanged over time (Figs. 2, 3) . HbA1c concentration of less than the 53 mmol/mol (7.0%) target in the 12 months prior. The inability to achieve good glycaemic control in clinical practice with insulin therapy has previously been described; Nichols et al. [20, 21] found that only 30.0-40.0% of insulin-treated patients were well-controlled;
Characteristics of Patients who Start BB Insulin
Comparative Analysis
further, Nichols et al. [20] showed that pre-insulin levels of HbA1c were the main factor in determining whether the target HbA1c level was reached after insulin initiation. The patients in this study remained at high HbA1c levels irrespective of whether they remained on their BB insulin regimen or switched to a premixed insulin. Even in randomised controlled clinical trials, less than half of the patients with T2DM treated with BB were able to achieve an HbA1c level of \7.0% [22] .
The second part of our study then focused on patients who did not achieve HbA1c levels of \7.0 with BB and either remained on that regimen or switched to premixed insulin. All clinical factors investigated indicated that the group of patients who switched to premixed insulin were less well-controlled. The HbA1c and BMI measurements at 12 months of follow-up showed that the HbA1c concentration and BMI remained fairly constant for both groups. Despite the difference between the groups at baseline, we found little evidence that the type of insulin therapy was associated with any meaningful changes in key clinical outcomes over time.
This result suggests that the simplified regimen afforded by premixed insulin allowed patients who switched therapeutic regimen to maintain similar HbA1c levels to that achieved with a BB regimen prior to the switch.
While BB therapy is regarded as the gold standard for insulin therapy, its benefit may only appear if the patient understands the technicalities of such a complex regimen, including the need for frequent blood glucose monitoring and insulin dose adjustments. Donnelly et al. [11] showed that adherence to insulin was a significant predictor of HbA1c.
Similarly, the ADA/EASD approach to starting and adjusting insulin shows that BB therapy might not be the best 'end of line' therapy for many, and premixed insulin may be an acceptable alternative in achieving glycaemic control [4] .
A recent meta-analysis by Wang et al. [14] found that among insulin-naïve patients with T2DM, premixed insulin was equally as effective as BB insulin in reducing HbA1c. In a UK-wide evaluation in the secondary care setting, the clinical use of biphasic insulin lispro 50/50
showed the greatest HbA1c reduction in those patients who were previously treated with a BB regimen [13] . Reasons for remaining on BB therapy whilst having high HbA1c levels were not investigated in this study. The ADA/EASD guidelines recommend a patient-centred approach in the choice of pharmacological agents, including considerations on efficacy, cost, potential side effects, weight, comorbidities, hypoglycaemia risk and patient preferences [4] . Similarly, in the UK, the NICE guidelines for the management of T2DM in adults [3] recommend that an individualised approach to diabetes care is followed, which includes personal preferences, comorbidities and the risk of polypharmacy. As GPs are the main managers of T2DM in the UK, the strengths of this study include the use of a large primary care database representative of the UK population with a range of available outcome measures [23] . To our knowledge this study is the first to describe outcomes of patients switching from BB to a premixed insulin regimen in the primary care
setting. The findings are consistent with those of other studies looking at glycaemic control in that they show that patients with high HbA1c levels find it difficult to reach target levels irrespective of the treatment type [20] [21] [22] .
Still the use of CPRD data carried some limitations in terms of data availability. 
